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Spatiotemporally restricted arenavirus replication
induces immune surveillance and type I interferon-
dependent tumour regression
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Percy A. Knolle7, Guido Wollmann8, Dorothee von Laer8, Ingo Drexler9, Jessica Rathbun10, Paula M. Cannon10,
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Immune-mediated effector molecules can limit cancer growth, but lack of sustained immune
activation in the tumour microenvironment restricts antitumour immunity. New therapeutic
approaches that induce a strong and prolonged immune activation would represent a major
immunotherapeutic advance. Here we show that the arenaviruses lymphocytic choriomeningitis
virus (LCMV) and the clinically used Junin virus vaccine (Candid#1) preferentially replicate in
tumour cells in a variety of murine and human cancer models. Viral replication leads to
prolonged local immune activation, rapid regression of localized and metastatic cancers, and
long-term disease control. Mechanistically, LCMV induces antitumour immunity, which depends
on the recruitment of interferon-producing Ly6Cþ monocytes and additionally enhances
tumour-speciﬁc CD8þ T cells. In comparison with other clinically evaluated oncolytic viruses
and to PD-1 blockade, LCMV treatment shows promising antitumoural beneﬁts. In conclusion,
therapeutically administered arenavirus replicates in cancer cells and induces tumour regression
by enhancing local immune responses.
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E
ffective treatment of advanced tumours remains a major
challenge because of limited availability of tumour-speciﬁc
agents and development of drug resistance. Next to chemo-
therapy and targeted therapies, immunotherapy is one promising
approach to treat cancer1.
The immune system can directly attack tumour cells via
antigen-speciﬁc cytotoxic CD8þ T cells, activated natural killer
(NK) cells or antibody-mediated cytotoxicity2,3. In addition,
cytokines such as tumour necrosis factor-a, interferon (IFN)-g
or type I IFN (IFN-I) can directly exert antiproliferative and
pro-apoptotic effects on tumour cells, or indirectly, through
modulation of the tumour microenvironment1,4. Despite the
physiological existence of these potent anticancer effector
molecules, neoplastic cells can survive and expand in immune-
competent individuals. Escape from immune surveillance is
mainly explained by limited immune activation or tumour-
induced immunosuppression within the microenvironment2.
Effective induction of strong and sustained immune activation
at the tumour sites would therefore be a promising therapeutic
approach against cancer.
Viruses have a very high capacity to activate the innate and
adaptive immune system. This is mainly explained by three
mechanisms. First, viruses introduce new antigens to the immune
system, which are recognized by the host as foreign5. Second,
viruses carry ligands for pattern recognition receptors, which
trigger the innate immune system5. Third, viruses are usually
drained from peripheral sites to the lymphatic system where they
undergo spatiotemporally restricted replication in antigen-
presenting cells and thereby speciﬁcally activate innate and
adaptive immune cells6,7.
Arenaviruses are enveloped and pleiomorphic, with a diameter
of 60–300 nm and two single-stranded RNA genome segments.
The non-cytopathic arenaviruses propagate rapidly without
directly harming susceptible tissues. Rather, it is the immune
response against infected cells that may cause severe tissue
damage and disease symptoms8,9. Arenaviruses can infect
humans and disease outcome depends on the speciﬁc strain.
Lassa virus and Junin virus are responsible for the Lassa and
Argentine haemorrhagic fever, respectively10. In contrast, human
infection with the arenavirus strains lymphocytic chorio-
meningitis virus (LCMV, strain WE) and Candid#1, which is a
clinically applied vaccine virus to protect against Argentine
haemorrhagic fever, is usually asymptomatic or causes non-
speciﬁc symptoms such as fever and malaise11,12. LCMV-WE
induces a strong T-cell response, which can be antitumoural in
cancer models13,14. Therefore, recombinant single-cycle LCMV is
considered a vaccine virus with potential to immunize against
tumour antigens15.
Here we investigate whether neoplastic cells can serve as
natural reservoir for arenavirus replication and whether such
replication can induce spatiotemporally restricted innate immu-
nity, virus-speciﬁc and tumour-speciﬁc adaptive immune activa-
tion. We show that LCMV and Candid#1 preferentially replicate
in cancer cells and induce immune surveillance resulting in
IFN-I-dependent tumour regression.
Results
Arenavirus preferentially replicates in cancer cells. In recent
times, we found that fast replication of arenavirus in dendritic
cells led to massive activation of the innate and adaptive immune
system6. As cancer cells are characterized by altered cell cycle,
metabolism and translation16 relative to their normal counter-
parts, we wondered whether arenaviruses might preferentially
replicate in tumour cells and whether this affects the anti-
tumoural immune response. To explore the replication capacity
of arenaviruses in tumour cells, we infected human cancer cells
and the healthy parenchymal counterpart they originated from
with the non-cytopathic LCMV. Primary hepatocytes, colon
epithelial cells, melanocytes and bronchial epithelial cells showed
limited LCMV replication as compared with malignant cells
originating from these tissues (Fig. 1a,b). Having established that
arenaviruses preferentially replicate in tumour cells, we next
infected a tumorigenic cell line that is capable of forming tumours
in a syngeneic setting using immune-competent mice.
Speciﬁcally, we infected the murine squamous oropharynx
carcinoma cell line (MOPC)17 with LCMV-WE in vitro. Within
72 h, all cancer cells revealed LCMV replication without affected
cell survival (Fig. 1c and Supplementary Fig. 1). Next, we
established palpable tumours in C57BL/6 mice by subcutaneous
injection of MOPC cells and infected the mice with 2 104
plaque-forming unit (PFU) LCMV peritumourally. Immuno-
ﬂuorescence revealed viral replication within these tumours, but
not in other regions of the skin (Fig. 1d). The presence of
subcutaneous MOPC tumours signiﬁcantly increased local and
splenic virus propagation in C57BL/6 mice (Fig. 1e) and
virus persisted in tumours for more than 30 days (Fig. 1f). To
generalize this phenomenon, we analysed the replication of
LCMV in a broad panel of other murine cancer models.
Peritumoural injection of LCMV in subcutaneously established
B16F10 melanoma18 and MC38 colon cancer19, as well as
intravenous administration of LCMV in endogenously hepa-
tocellular carcinoma bearing LoxP-TAg20 resulted in intra-
tumoural propagation of LCMV (Fig. 1g–i).
B-Myb promotes arenavirus replication. Lack of IFN-I receptor
and deregulated IFN signalling is proposed to be one mechan-
ism accounting for enhanced viral replication and IFN-unre-
sponsiveness in cancer cells21,22. However, analysis of the
Cancer Genome Atlas (TCGA) database revealed high
expression of Ifnar1 and Ifnar2 in a range of cancer entities
(Supplementary Fig. 2a) and human cancer cell lines
showed expression of Ifnar1 and Ifnar2 (Supple-
mentary Fig. 2b). To test whether human cancer cell lines can
respond to some of the many murine IFN-I in a xenograft
system, we treated Sw480 cells and HeLa cells with different
IFN-I subtypes in vitro. Sw480 and HeLa cells responded to
murine IFN-a2 and human IFN-a4 but not to murine IFN-a4
(Supplementary Fig. 2c). Moreover, all the murine cancer cells
tested in our in vivo studies expressed Ifnar1 (Supplementary
Fig. 2d). In comparison with MC38, B16F10, LoxP-TAg and
MT/ret, MOPC cells showed highest expression levels (Supple-
mentary Fig. 2d).
We hypothesized that the fast cell cycle and metabolism of
cancer cells promote replication of arenavirus and thereby
explains the fast propagation of LCMV in cancer cells. Recent
reports show that the expression of the cell cycle kinase CDK2
is associated with increased HIV replication in myeloid and
lymphoid cells23. CDK2 phosphorylates B-Myb, which enhances
the transcription of a number of genes involved in cell proli-
feration and metabolism24,25. To explore whether B-Myb (Mybl2)
is one factor in cancer cells contributing to enhanced arenavirus
replication, we studied Mybl2 expression and phosphorylation
in cancer tissues and non-malignant controls. Indeed, tumours
expressed higher Mybl2 RNA levels and exhibited increased
B-Myb phosphorylation (Supplementary Fig. 2e,f). The presence
of B-Myb correlated with higher expression of known viral
host factors in MOPC tumours than control tissue (Supple-
mentary Fig. 2g). In line, knockdown of B-Myb limited LCMV
replication (Supplementary Fig. 2h). Therefore, we concluded that
B-myb overexpression is one viral susceptibility factor in cancer
cells.
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Arenavirus replication leads to tumour regression. Next we
wondered whether LCMV replication in tumour cells inﬂuences
tumour progression. We infected C57BL/6 mice bearing small
tumours with LCMV peritumourally. Untreated control tumours
grew robustly and mice succumbed to the tumour within 30 days
(Fig. 2a). Peritumoural LCMV injection completely abolished
tumour growth and mice survived relapse-free for an observa-
tional time of 80 days (Fig. 2a), without virus- or tumour-related
symptoms. In mice bearing very advanced MOPC tumours,
LCMV infection induced considerable tumour regression and
signiﬁcantly prolonged survival (Fig. 2b). To explore the activity
of LCMV virotherapy in metastatic cancers, we compared local
and systemic virus administration in mice bearing simultaneous
MOPC tumours in the left shoulder and the right ﬂank. Peritu-
moural injection of LCMV in the right ﬂank resulted in virus
replication only in the ﬂank (Supplementary Fig. 3a). Systemically
administered LCMV reached both tumour sites (Supplementary
Fig. 3a). In agreement, intravenous LCMV application, but not
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Figure 1 | Arenavirus preferentially replicates and persists in cancer cells. (a) Immunoﬂuorescence in tissue-matched human normal untransformed and
tumour cells 2 days after LCMV infection (MOI 1) (n¼ 3 per group). Scale bar, 20mm. (b) Infectious virus particles in supernatants from human normal
(hN) untransformed and tumour cells, which were infected with LCMV (MOI 1) and analysed on indicated days (n¼ 6 per group). (c) Immunoﬂuorescence
of MOPC cells untreated or infected with LCMV (MOI 1) 72 h after infection (n¼ 3/group). Scale bar, 20mm. (d) Immunoﬂuorescence of tumours in
MOPC-tumour-bearing C57BL/6 mice (day  10) treated with or without 2 104 PFU LCMV peritumourally (LCMV, green; 4,6-diamidino-2-phenylindole
(DAPI), blue, n¼ 3 per group). Scale bar, 200mm. (e) Infectious virus particles in skin and spleen (day 8) of C57BL/6 mice or MOPC-tumour-bearing mice
(day  3) treated with 2 104 PFU LCMV subcutaneously (n¼4 per group). (f) LCMV-NP RNA in tumours of MOPC-tumour-bearing C57BL/6 mice (day
 10) treated with 2 104 PFU LCMV intratumourally (n¼8 per group). (g) Immunoﬂuorescence of tumours (day 7, n¼ 3) from B16F10-tumour-bearing
C57BL/6 mice (day  3) treated with or without 2 104 PFU LCMV peritumourally. Scale bar, 200mm. (h) Immunohistochemistry of tumours (day 7,
n¼ 3) from MC38-bearing C57BL/6 mice (day  3) treated with (n¼ 6) or without (n¼ 7) 2 104 PFU LCMV peritumourally. Scale bar, 200mm.
(i) Immunohistochemistry (day 6, n¼ 3) of livers from LoxP-Tag-tumour-bearing or WTmice, which were treated with or without 2 106 PFU LCMV
systemically. Scale bar, 200mm. Data are shown as mean±s.e.m. and analysed by unpaired Student’s t-test. *Po0.05, ***Po0.001 and ****Po0.0001.
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Figure 2 | Persistence of arenavirus leads to tumour regression. (a) Tumour diameter and survival of MOPC-tumour-bearing mice (day  3) treated with
or without 2 104 PFU LCMV peritumourally (n¼ 10 per group, three experiments pooled). (b) Tumour diameter and survival of MOPC-tumour-bearing
mice (day  10) treated with or without 2 104 PFU LCMV intratumourally (n¼ 10 per group, three experiments pooled). (c) Tumour diameter of the
shoulder tumour from C57BL/6 mice receiving simultaneously subcutaneously 5 105 MOPC cells in the ﬂank and shoulder (day  3), treated without
(n¼ 5) or with 2 104 PFU LCMVgiven into the ﬂank (n¼4) or intravenously (n¼ 5). (d) Tumour diameters (shoulder and ﬂank) and survival of WTmice
bearing MOPC tumours simultaneously in the shoulder and ﬂank, treated with or without 2 106 PFU LCMV intravenously on day 0 (n¼6 per group).
(e) Tumour diameter from MC38-bearing C57BL/6 mice (day  3) treated with (n¼6) or without (n¼ 7) 2 104 PFU LCMV peritumourally. (f) Tumour
diameters from B16F10-tumour-bearing C57BL/6 mice (day  3) treated with or without 2 104 PFU LCMVperitumourally (n¼6 per group). (g) Number
of melanomas (day 15) in MT/ret mice treated with (n¼ 3) or without (n¼4) 2 104 PFU LCMVsystemically. (h,i) Representative picture (h, day 6, n¼ 3)
and quantiﬁcation of tumour nodules (i, day 6 n¼ 3, day 20 n¼ 6) of/in the livers from LoxP-Tag-tumour-bearing or WTmice, which were treated with or
without 2 106 PFU LCMV systemically. Scale bar, 0.5 cm. Data are shown as mean±s.e.m. and analysed by unpaired Student’s t-test. *Po0.05,
**Po0.01, ***Po0.001 and ****Po0.0001.
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local LCMV injection into the ﬂank tumour, induced regression
of distant shoulder tumours (Fig. 2c). Conclusively, control of
multiple tumour sites and prolonged survival of mice with
advanced stage metastatic tumours can be achieved by systemic
LCMV therapy (Fig. 2d). Next, we analysed the antitumoural
activity of LCMV against a broad panel of murine cancer models
including MC38 colon cancer19, B16F10 melanoma18, the
endogenous hepatocellular carcinoma model LoxP-TAg20 and
spontaneous MT/ret melanoma model26. Peritumoural injection
of LCMV limited the growth of subcutaneous MC38 (Fig. 2e) and
B16F10 melanoma tumours (Fig. 2f). To test the activity of
LCMV virotherapy on spontaneously developing malignant
melanomas in the MT/ret mouse model26, LCMV was injected
intravenously once cutaneous tumours became palpable.
Strikingly, LCMV-infected MT/ret mice developed signiﬁcantly
less macroscopically visible tumour nodules than untreated mice
(Fig. 2g). Next, we studied LCMV virotherapy in endogenously
developing liver cancers. Nine-month-old LoxP-TAg mice
harbouring palpable liver tumours either received an
intravenous injection of LCMV (2 106 PFU) or were left
untreated. Intriguingly, 20 days after LCMV injection tumour
nodules had largely disappeared (Fig. 2h,i). Consistent with these
ﬁndings, serum liver enzyme levels, which reﬂect tumour burden
in the liver, were signiﬁcantly lower in LCMV-treated LoxP-TAg
mice than in uninfected LoxP-TAg controls (Supplementary
Fig. 3b).
IFN-I was essential for tumour regression. To dissect whether
LCMV replication or LCMV-induced immune inﬁltration
impacts tumour growth, we studied tumour growth in Map3-
k14aly/aly mice, which have defective nuclear factor-kB signa-
lling and therefore lack lymph nodes and immune functions27.
LCMV-induced tumour regression was dependent on Map3k14
(Supplementary Fig. 4), suggesting that immune inﬁltration is
crucial. Indeed, LCMV replication induced a dense inﬁltrate
composed of T cells (CD90.2, CD4 and CD8) and inﬂammatory
Ly6Cþ monocytes (Fig. 3a). Strong inﬁltrates of Ly6Cþ mono-
cytes were detected in draining lymph nodes (dLNs) of LCMV-
treated subcutaneous MOPC tumours (Fig. 3b). Monocytes
have the plasticity to execute diverse effector functions and are
therefore equipped to inhibit tumour growth28. As inﬂamma-
tory monocytes also produce IFN-I after innate sensing29,
we postulated that LCMV-induced IFN-I secretion in Ly6Cþ
monocytes impacts tumour growth. To analyse IFN-I production
in Ly6Cþ monocytes, we established MOPC tumours in IFN-b
reporter mice (IFNbmob/mob) and infected them with LCMV30.
IFN-b-producing Ly6Cþ monocytes were detected in the dLN of
tumour-bearing mice after infection with LCMV (Fig. 3c).
Ly6Cþ monocytes were further characterized as mPDCA-1hi,
CD11cmed and B220med (Fig. 3c), suggesting that they
were differentiated into IFN-I-producing cells31. Consistently,
quantitative real-time PCR (qRT–PCR) analysis revealed high
expression of IFN-I-associated genes in dLN after LCMV
infection, and IFN-a serum levels were enhanced in LCMV-
infected tumour-bearing mice (Fig. 3d,e). To dissect the role of
monocytes and IFN-I on tumour regression, we studied tumour
growth in mice depleted of myeloid cells in vivo using different
antibodies. First, we treated mice with an antibody against the
myeloid differentiation antigen Gr-1 (clone RB6-8C5), which
depletes Ly6Gþ and Ly6Cþ cells32–34 (Supplementary Fig.5a).
Another experimental group was treated with an antiLy6G
antibody (clone 1A8), which only binds to Ly6Gþ cells
(Supplementary Fig. 5b). Depletion of Ly6Cþ and Ly6Gþ cells
(monocytes and granulocytes) with clone RB6-8C5 abrogated
LCMV-mediated tumour suppression (Fig. 3f), whereas depletion
of Ly6Gþ cells (granulocytes) with clone 1A8 alone had no
impact on the antitumoural effect of LCMV (Supplementary
Fig. 5c). This suggests that monocytes are centrally involved in
LCMV-induced tumour regression. The role of monocytes was
conﬁrmed using Ccr2 / mice, which have reduced monocyte
numbers28 and in which LCMV-mediated tumour suppression
was signiﬁcantly blunted (Fig. 3g). To corroborate the involve-
ment of IFN-I in LCMV-mediated tumour regression, we used
Irf3 /xIrf7 / mice, which lack IFN-I induction after LCMV
infection35. LCMV infection failed to suppress tumour growth
in Irf3 /xIrf7 / mice (Fig. 3h), supporting the functional
importance of IFN-I for the antitumour effect of arenavirus
infection. Analysis of T cells (Supplementary Fig. 6a), B cells
(Supplementary Fig. 6b) and NK cells (Supplementary Fig. 6c,d)
failed to reveal an impact of these immune cell subsets on LCMV-
induced control of early stage tumours, suggesting that IFN-I acts
independent of these cell subsets on tumour regression.
Monocyte recruitment and IFN-I induction in human cancer.
To gain further insights into the possible translation of arena-
viruses to human cancer therapy we studied primary tumour
biopsies from 34 patients with oropharyngeal cancers. Multigene
expression analysis by qRT–PCR revealed a strong correlation
between the expression of human monocytic markers CD14 or
CD16 and diverse IFN-I-related genes such as IFNB1, USP18 and
IRF7 (Supplementary Fig. 7a,b), indicating that human monocytic
inﬁltrates can produce IFN-I within human tumour tissues. To
investigate whether our observation is expandable to different
human cancer types, we accomplished a gene-set enrichment
analysis (GSEA) by using the human cancer TCGA database.
Indeed, CD14þ cell populations were enriched for IFN-I-related
genes (Supplementary Fig. 7c)36.
Ambiguous role of CD8þ T cells in cancer virotherapy. So far,
we found that monocytes and IFN-I were essential factors needed
for tumour regression, and that T cells were dispensable for
LCMV cancer therapy of early stage tumours. However, we
wondered how the presence of CD8þ T cells might also
contribute to tumour regression. We hypothesized that CD8þ
T cells have a dual role in arenavirus-based therapy. On the one
hand, they are essential in controlling virus, therefore limiting
viral persistence. On the other hand, tumour-speciﬁc CD8þ
T cells might be activated by arenavirus and might therefore
contribute to tumour regression. Indeed, we found that virus-
speciﬁc CD8þ T cells were induced during arenavirus therapy
(Fig. 4a). The presence of virus-speciﬁc CD8þ T cells limited
replication and effectiveness of LCMV therapy during systemic
treatment (Supplementary Fig. 8a). Conversely, lack of virus-
speciﬁc CD8þ T cells prolonged the antitumoural effects of
IFN-I and enhanced survival even in an advanced tumour stage
(Supplementary Fig. 8b,c).
To analyse the role of LCMV on tumour-speciﬁc CD8þ
T cells, we infected mice bearing Ovalbumin-expressing B16F10
tumours in the presence of tumour-speciﬁc CD8þ T cells. LCMV
enhanced expression of IL-2Rb (CD122) and IL-7Ra (CD127) on
tumour-speciﬁc CD8þ T cells, both of which promote cell
survival (Fig. 4b)8. Moreover, LCMV infection enhanced tumour-
speciﬁc CD8þ T cells in tumour inﬁltrates after vaccination with
tumour antigen (Fig. 4c). Accordingly, the combination of LCMV
and tumour-speciﬁc CD8þ T cells was most effective in
suppressing tumour growth in the B16F10 melanoma model
and in the EL4 subcutaneous lymphoma model (Fig. 4d,e). This
suggests that LCMV enhances the inﬁltration and function of
tumour-speciﬁc CD8þ T cells, which contributes to LCMV-
mediated tumour regression.
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Reduced vasculature correlates with LCMV treatment. Next, we
investigated the mechanism of IFN-I-induced tumour suppres-
sion in our models. As MOPC cells express the IFN-a/b receptor
subunit 1 (IFNAR1) (Supplementary Fig. 2d), we analysed
LCMV-induced tumour regression in Ifnar / mice, which are
deﬁcient in the IFN-I receptor. LCMV infection equally
suppressed tumour growth in wild type (WT) and Ifnar /
mice (Supplementary Fig. 9), suggesting that IFN-I secreted by
inﬁltrating Ly6Cþ monocytes directly acts on tumour cells. As
IFN-Is are potent inhibitors of tumour associated angiogenesis37,
we studied the expression of angiogenic factors by tumour cells in
relation to LCMV treatment. Interestingly, almost all angiogenic
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regulators studied were suppressed by LCMV infection (Supple-
mentary Fig. 10a). Moreover, CD31þ vessel formation was
severely blunted in LCMV-infected tumours (Supplementary
Fig. 10b), leading to reduced microvessel density (MVD) and
increased vessel-to-vessel distances (Supplementary Fig. 10c).
Consistent with reduced angiogenesis, we observed hypoxic areas
in LCMV-treated tumours (Supplementary Fig. 10d) that were
characterized by limited tumour cell proliferation and increased
apoptosis (Supplementary Fig. 10e).
Arenaviruses induce regression of human tumours. To explore
whether arenavirus therapy could be translated to the human
system, we used human xenograft models in NOD/SCID mice.
Peritumoural LCMV injection led to regression of subcutaneously
established HeLa and FaDu tumours in NOD/SCID mice
(Fig. 5a,b). Next, we studied the clinically used Junin virus
vaccine, Candid#1 (refs 11,12). Candid#1 replicated in Sw480-
and HepG2-tumours in vivo (Fig. 5c,d). Infection with LCMV
and with Candid#1 limited growth of Sw480 tumours (Fig. 5e).
Similarly, Candid#1 limited growth of HepG2 and Sw872
tumours (Fig. 5f,g). These data suggest that the vaccine virus
Candid#1 has antitumoural properties much similar to the
laboratory strain LCMV-WE.
LCMV is superior to oncolytic viruses and PD1 blockade. Next,
we compared LCMV with two oncolytic viruses presently in clinical
or preclinical development: a chimeric variant of vesicular stoma-
titis virus (VSV-GP)38 and a recombinant TK-depleted vaccinia
virus (TK VACV-GFP/LacZ, rVACV)39. Although VSV-GP is
currently being developed (www.viratherapeutics.com), another
very similar VSV variant (VSV-IFN) is being investigated in a
Phase I study for hepatocellular carcinoma (ClinicalTrials.gov
NCT01628640). rVACV is so far tested as a double deletion mutant
(TK and VGF ) in a phase I study, with patients with advanced
solid tumours40. In the MOPC tumour model, intravenous and
intratumoural application of VSV-GP and rVACV showed limited
antitumoural effects when compared with LCMV (Fig. 6a,b). Even
a 100-fold higher dose of VSV-GP or rVACV did not reach the
efﬁcacy of LCMV-induced tumour regression in the MOPC
tumour model (Fig. 6b). In line, human Sw480 xenografts were
more susceptible to intratumoural LCMV therapy than to VSV-GP
or rVACV (Fig. 6c). Next, we analysed the effects of PD-1 blockade
together with LCMV treatment. We observed strong expression of
PD-L1 in MOPC tumours (Fig. 6d). Blockade of PD-1 (in Pdcd1 /
mice) had no impact on tumour regression in the MOPC model
(Fig. 6e). In contrast, combination of PD-1 blockade with LCMV
had the strongest impact on tumour regression in advanced
tumour stage (Fig. 6e).
Discussion
The ability of viruses to kill cancer cells has been recognized for
several decades and is supported by recent Food and Drug
Administration and European Union (EU) approval of an
oncolytic herpesvirus (Talimogene laherparepvec, Amgen,
Inc.)41. The speciﬁc mechanisms of virotherapy have long been
considered to be directly oncolytic. Recently, it was recognized
that induction of an inﬂammatory response contributes to virus-
mediated tumour regression42–49. In cancer therapies with
oncolytic viruses, this is considered to be a limited collateral
effect. By contrast, in our study, we provide evidence that a
powerful immune response itself induced by arenavirus
replication may lead to complete tumour regression.
Treatment with a non-oncolytic arenavirus is advantageous in
inducing sustained immune surveillance. First, an arenavirus such
as LCMV will not kill the host cell by direct cytopathic effects.
Therefore, virus replication is maintained until an immune
response is induced within the tumour tissue. Second, arenavirus
replication cannot solely be limited by a strong IFN-I
response9,50,51. In addition, LCMV usually fails to induce rapid
neutralizing antibodies52. Thus, arenavirus replication in tumours
can only be controlled by inﬁltration of virus-speciﬁc CD8þ
T cells. Consequently, as long as CD8þ T cells do not inﬁltrate
the tumour, arenaviruses can replicate for several days or weeks
even if tumour cells respond to IFN-I. In a direct comparison of
the IFN-I-responsive tumour models MOPC and Sw480, we
found that LCMV was therapeutically more potent than the
oncolytic viruses VSV-GP and rVACV. These results could
have been expected, because, in contrast to LCMV, VSV-GP and
rVACV require defects in the IFN pathway for efﬁcient
replication in tumour cells53–55. Consequently, arenavirus
therapy could ﬁll a gap in virotherapy in the treatment of
IFN-I-responsive cancers. Careful characterization of IFN-I
responsiveness and additional LCMV host factors may guide
the selection of patients suitable for LCMV cancer therapy.
Treatment with arenaviruses might also have certain dis-
advantages. The broad tropism of arenaviruses56 might induce
adverse events. Live arenaviruses could also replicate in healthy,
non-malignant tissue. This replication could induce an immune
response in normal tissue, leading to immunopathological side
effects9,52. Although 45% of humans show evidence of previous
LCMV exposure without severe symptoms10, especially in
highly immunocompromised patients overwhelming replication
of attenuated vaccine virus could lead to life-threatening
disease52,57 or to gain of selection mutants of the virus58. Both
risks can be limited by intervention with neutralizing antibodies
against the arenavirus strain or antiviral therapy57. In our murine
models we observed initially enhanced LCMV replication in the
presence of tumours, but viral replication lead to an immune
response that was capable to control intratumoural virus load.
Figure 3 | IFN-I was essential for arenavirus-induced tumour regression. (a) Immunoﬂuorescence (day 10) of tumours from MOPC-tumour-bearing
C57BL/6 mice (day  10) treated with or without 2 104 PFU LCMVperitumourally (n¼ 3/group). Scale bar, 200mm. (b) Immunohistochemistry of dLNs
from MOPC-tumour-bearing mice treated with 2 104 PFU LCMVsubcutaneously (n¼ 3/group). Scale bar, 200mm. (c) Representative FACS blots (day 2)
from dLNs of MOPC-tumour-bearing C57BL/6 mice (day  3) and IFN-b-reporter mice (IFNbmob/mob) treated with 2 104 PFU LCMV peritumourally
(day 0, n¼4 per group). Grey area indicates isotype control. (d) qRT–PCR analysis of dLNs (day 3) from MOPC-tumour-bearing C57BL/6 mice (day  3)
treated with or without 2 104 PFU LCMV peritumourally (n¼ 3 per group). (e) IFN-a serum ELISA (day 3) from MOPC-tumour-bearing C57BL/6 mice
(day  3) treated with or without 2 104 PFU LCMV (n¼4 per group). (f) Tumour diameters of MOPC-tumour-bearing C57BL/6 mice (day  3) injected
with or without anti-Ly6CþG antibody (200mg, days  2, 2 and 7) and treated with (n¼6 per group) or without (n¼6 control; n¼ 7 anti-Ly6CþG-dep.)
2 104 PFU LCMV peritumourally (two experiments pooled). (g) Tumour diameters of MOPC-tumour-transplanted WT and Ccr2–/– mice (day  3)
treated with (n¼ 9 per group) or without (n¼6 per group) 2 104 PFU LCMV peritumourally (two experiments pooled). (h) Tumour diameter from
MOPC-tumour-bearing WT and Irf3–/– x Irf7–/– mice (day  3) treated with or without 2 104 PFU LCMV peritumourally (n¼6 per group, two
experiments pooled). Data are shown as mean±s.e.m. and analysed by unpaired Student’s t-test. Survival is shown in Kaplan–Meier method and analysed
by log-rank test. NS, nonsigniﬁcant; *Po0.05, **Po0.01 and ***Po0.001.
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Figure 4 | CD8þ T-cell activation contributes to arenavirus-mediated tumour regression. (a) LCMV-speciﬁc CD8þ T cells in the blood (day 8) of
MOPC-tumour-bearing or control mice, which where infected with LCMV (n¼ 3). (b) Expression of PD-1, IL-2Rb and IL-7Ra on tumour-speciﬁc CD8þ T
cells (OT1, day 8) of B16-OVA-tumour-bearing C57BL/6 mice (day  10) transferred with 5 106 OT1 splenocytes (day  1) and additionally treated with
(n¼ 5) or without (n¼ 3) LCMV (i.t. 2 104 PFU). (c) Total numbers of tumour-speciﬁc (OVA), antigen-exposed (CD44þ ) CD8þ T cells (day 2) in
tumours of B16-OVA-tumour-bearing C57BL/6 mice (day  13), which were vaccinated with ovalbumin (200mg, day  3, i.v.) with or without CpG (20 mg,
day  3, i.v.) and additionally treated with or without LCMV (5 105 PFU, i.t., n¼ 8). (d) Tumour diameter and survival of B16-OVA-tumour-bearing
C57BL/6 mice (day  10) treated with (n¼ 5 per group) or without (n¼4 per group) 5 106 OT1 splenocytes (day  1) and additionally treated with or
without LCMV (i.t. 2 104 PFU). (e) Tumour diameter and survival of EL4-OVA-lymphoma-bearing C57BL/6 mice (day 6) treated with (n¼ 7 per
group) or without (n¼4–5 per group) 5 106 OT1 splenocytes (day  1) and additionally treated with or without LCMV (i.t. 2 106 PFU, day 0). Data are
shown as mean±s.e.m. and analysed by unpaired Student’s t-test. NS, nonsigniﬁcant; *Po0.05, **Po0.01 and ***Po0.001.
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Figure 5 | LCMV and arenavirus vaccine Candid#1 induce regression of human tumours. (a) Tumour diameter from HeLa-tumour-bearing NOD/SCID
mice (day 8) treated with or without 2 104 PFU LCMV intratumourally (n¼8 per /group). (b) Tumour diameter and survival from FaDu-tumour-
bearing NOD/SCID mice (day  10) treated with or without 2 106 PFU LCMV i.t. (n¼ 5 per group) (c) Immunoﬂuorescence (day 10) of tumours from
Sw480-tumour-bearing NOD/SCID mice (day  10) treated with or without 2 104 PFU Candid#1 intratumoural (n¼ 3 per group). Scale bar, 200mm.
(d) Immunoﬂuorescence (day 10, n¼ 3 per group) from HepG2-tumour-bearing NOD/SCID mice treated with or without 5 105 PFU Candid#1
intratumourally. Scale bar, 200mm. (e) Tumour diameter and survival from Sw480-tumour-bearing NOD/SCID mice (day  11) treated with (n¼ 5) or
without (n¼ 6) 5 105 PFU LCMV or 2 104 PFU Candid#1 (n¼ 7) intratumourally. (f) Tumour diameter from HepG2-tumour-bearing NOD/SCID mice
treated with (n¼ 5) or without (n¼4) 5 105 PFU Candid#1 intratumourally. (g) Tumour diameter (untreated n¼6; treated n¼ 8) and survival (n¼ 5 per
group) from Sw872 liposarcoma-bearing NOD/SCID mice treated with or without 5 105 PFU Candid#1. Data are shown as mean±s.e.m. and analysed by
unpaired Student’s t-test. Survival is shown in Kaplan–Meier method and analysed by log-rank test. *Po0.05, **Po0.01 and ****Po0.0001
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Using the hepatotropic LCMV strain WE, we observed some viral
replication in livers of B16F10 mice, but liver enzymes were under
the upper limit of normal when tested 20 days after virus
injection. LCMV-treated WT, transgenic and NOD/SCID mice
did not show any virus or immunopathology related signs of
sickness. Nevertheless, the clinical applicability of arenavirus-
based treatment has to be carefully evaluated.
We found that arenavirus-based tumour therapy required
IFN-I. IFN-I has substantial antiproliferative activity in different
cancer types59. Three major mechanisms could be responsible for
these effects: ﬁrst, IFN-I can directly induce cell cycle arrest in
cancer cells60,61; second, IFN-I can trigger an antigen-speciﬁc
antitumour immune response4; and third, IFN-I can inhibit
angiogenesis37. We found in the MOPC model that arenavirus
infection enhanced IFN-I induction, enhanced antitumour
immune response and limited angiogenesis.
LCMV treatment did not inﬂuence PD-L1 expression in the
tumour nor PD-1 expression on CD8þ T cells. In contrast, it
b
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Figure 6 | LCMV induces the strongest tumour regression compared with oncolytic viruses and PD1 blockade. (a,b) Tumour diameter and survival of
MOPC-tumour-bearing C57BL/6 mice (day  10) treated intratumourally (a) or intravenously (b) with LCMV, VSV-GP, rVACV or vehicle (n¼ 5 per
group). (c) Tumour diameter and survival of Sw480-tumour-bearing NOD/SCID mice treated i.t. with 2 106 PFU of LCMV, rVACV, VSV-GP or MOCK
control (n¼ 5 per group). (d) Immunoﬂuorescence of tumours from MOPC-tumour-bearing mice (day  10) treated with or without 2 104 PFU LCMV
peritumourally on day 0 (LCMV, green; red PD-L1; n¼ 3 per group). (e) Tumour diameter and survival of MOPC-tumour-bearing C57BL/6 and Pdcd1–/–
mice (day  10) treated with or without 2 104 PFU LCMV peritumourally on day 0 (n¼ 5 per group). Data are shown as mean±s.e.m. and analysed by
unpaired Student’s t-test. Survival is shown in Kaplan–Meier method and analysed by log-rank test. NS, nonsigniﬁcant; *Po0.05, **Po0.01 and
***Po0.001; scale bar, 200mm.
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enhanced tumour-inﬁltrating tumour-speciﬁc CD8þ T cells, as
well as survival signals in these cells. In line with these ﬁndings,
a combination of CD8þ T cells and LCMV, or a combination of
PD-1 blockade and LCMV, were the most effective tumour
treatments.
To date, different strains of LCMV are in laboratory use for the
investigation of acute and chronic viral infections, as well as an
efﬁcient tool to enhance and examine T-cell responses in murine
models of infection, autoimmune disease and cancer13,15,56,62. For
example, Schadler et al.14 used the low replicative ‘neuro-
tropic strain’ LCMV Armstrong (LCMVarm) in addition to
lipopolysaccharide (LPS) and anti-CD3, to increase
thrombospondin-1 (Tsp1) in T cells and tested the antitumoural
potency of Tsp1. In their study, growth of B16F10 melanomas was
observed for approximately 2 weeks after LCMVarm infection and
antitumoural effects after LCMVarm administration were
dependent on Tsp1 and T cells. By contrast, our studies with the
‘viscerotropic strain’ LCMV-WE revealed that its potent
antitumour activity was mediated via IFN-I and was T-cell
independent. The differences in mechanism and potency
underlying the antitumour effects of LCMV in the two studies
may reﬂect strain-dependent differences between the different
arenaviruses used, the impact of the speciﬁc cancer types examined
and the different timepoints used. Thus, similar to Schadler et al.14
we observed an impaired antitumoural effect of LCMV in
Rag1 / mice compared with WT mice within the ﬁrst 2
weeks after LCMV treatment of established tumours, indicating the
involvement of T cells (Supplementary Fig. 8b, middle panel).
However, in the long-term observation of approximately 80 days,
we show that the absence of T cells is beneﬁcial for LCMV-WE
therapy (Supplementary Fig. 8b). Moreover, we based our studies
largely on the mechanism of antitumoural action of LCMV in a
murine head and neck cancer model (MOPC), whereas Schadler
et al.14 used malignant melanoma, where effective immuno-
therapies mainly depend on tumour-speciﬁc T cells63. This may
also explain the lower efﬁciency and efﬁcacy of IFN-dependent
LCMV therapy on B16F10 (Fig. 2f) compared with MOPC
(Fig. 2a) or MC38 colon cancer (Fig. 2e).
Studies from others, such as Ochsenbein et al.13 and Flatz
et al.15, used LCMV as a model to activate tumour-speciﬁc CD8þ
T cells. In agreement with their work, we use transgenic tumour
models to show that OVA-speciﬁc T cells show enhanced
antitumoural effects, when additional T-cell activation via LCMV
infection is performed. However, we demonstrate that T cells
exhibit an ambiguous role in LCMV treatment of tumours. In the
presence of tumour-speciﬁc T cells, LCMV enhances antitu-
moural immune defenses, but the presence of virus-speciﬁc
T cells limits the antitumoural activity of LCMV by controlling
viral replication (Supplementary Fig. 4). Moreover, studying the
mechanism of antitumoural action of LCMV-WE, we found
that T cells were largely dispensable in our MOPC tumour model
in Tcrab / , Rag1 / and NOD/SCID mice. Rather,
LCMV-induced antitumour immunity depends mainly on the
recruitment of IFN-producing Ly6Cþ monocytes.
We found that monocytes, which inﬁltrate into human
tumours, have the ability to produce IFN-I. It remains an open
question whether local or systemic injection of Candid#1 in
humans could be similar to mice in enhancing the local IFN-I
response and thereby inducing tumour regression. In recent times
it was found that IFN-free therapy of chronic hepatitis C
virus-related hepatocellular cancer leads to unexpected early
tumour recurrence64. This ﬁnding underlines the potent
antitumoural effects of IFN-I on cancer growth during
persistence of virus.
In conclusion, we found that locally or systemically adminis-
tered arenaviruses preferentially replicate in murine and human
cancer cells, and strongly induce a local innate immune
response, leading to effective regression of disseminated cancers
in vivo.
Methods
Human material. Formalin-ﬁxed, parafﬁn-embedded primary tumour tissue was
retrieved from the archives of the Department of Otorhinolaryngology, University
Hospital Essen, from patients who had signed their informed consent according to
the Declaration of Helsinki and with approval from the institutional review board
at the University Hospital Essen.
Viruses. The LCMV strain WE and VSV (strain Indiana) were kindly provided by
Rolf Zinkernagel (Institute of Experimental Immunology, ETH, Zurich, Switzer-
land). LCMV was propagated in L929 cells, which were purchased from ATCC
(CCL-1). VSV was propagated in BHK cells, which were bought from ATCC
(CRL-8544). Virus titres in tissue of infected mice were measured using plaque
assays. For detection of virus in the skin, about 10mg of the infected skin area was
used. Candid#1 was grown in Vero E6 cells purchased from ATCC (CRL-1586).
Recombinant VSV-GP (provided by Professor von Laer, Division of Virology,
Medical University Innsbruck, Austria) was generated as previously described38.
VSV-GP was grown on Vero cells under serum-free conditions. Recombinant
Tk Vaccinia virus strain Western Reserve containing the green ﬂuorescent
protein gene expressed under the P7.5 promoter within the Tk (thymidine kinase)
locus of the genome (originally provided by B. Moss, National Institutes of Health,
Bethesda, MD) was propagated, puriﬁed and titrated following standard
methodology65.
Cell lines and depletion antibodies. MOPC cells (murine oropharynx cancer)
were initially named MTEC and were provided by Dr H.J. Lee of the University of
Iowa. Cells were cultured in previously described culture medium17. MaMel66a
cells (human malignant melanoma) were provided by Professor Schadendorf66.
MC38-OVA (MC38 cells, murine colon carcinoma) and EL4-OVA cells
(murine ovalbumin-expressing lymphoma) were a kind gift of Bertrand Huard
(University Medical Center, Geneva, Switzerland). B16F10 cells (murine malignant
melanoma) were purchased from ATCC (CRL-6475). B16-OVA (OVA-expressing
B16 malignant melanoma cells) were provided by Professor P. Knolle, Technical
University, Munich, Germany. SW480 (human colon carcinoma, CCL-228) and
FaDu cells (human oropharyngeal carcinoma, HTB-43), A549 cells (human
bronchial carcinoma, CCL-185), HepG2 cells (human hepatoma, HB-8065) and
HeLa cells (human cervix carcinoma, CCL-2) were purchased from ATCC. SW872
cells were kindly provided from Professor Bauer (University Hospital, Essen,
Germany).
Human normal untransformed cells were purchased from ATCC (FHC
CRL-183), LONZA (NHBE CC-2540; HRE CC2556) and PromoCell (NHEM
C-12453), which were cultured and maintained according to the companies’
protocols.
Monoclonal ﬂuorescence-labelled antibodies against LCMV-NP (VL4)
and LCMV-GP (clone KL25), and unlabelled anti-NK1.1 antibodies were
produced in-house (Professor P.A. Lang, Heinrich Heine University, Du¨sseldorf,
Germany).
Anti-Ly-6G (1A8), anti-Gr-1 Ab (RB6-8C5) and anti-IFNAR1 (clone
MAR1-5A3) depletion antibodies were purchased from Bio X Cell. All
other antibodies used for immunoﬂuorescence are listed in Supplementary
Table 1.
Mice. C57BL/6J (Jackson Laboratory; 00664), Map3k14aly/aly (Professor Shibata,
Kyoto, Japan), Ifnar1 / (Jackson Laboratory; 028288), Tcrab / (Jackson
Laboratory; 002116), Jh / (Jackson Laboratory; 002438), Rag1 / (provided by
Professor P.A. Lang, Heinrich Heine University, Du¨sseldorf, Germany), Ccr2 /
(Jackson Laboratory; 004999), OT-1 (kindly provided by Professor J. Fandrey,
University Hospital, Essen) and Irf3 x Irf7 / (Provided by Professor Lo¨hning,
Charite Hospital Berlin) were maintained on the C57BL/6 background. IFNbmob/
mob mice (provided by Professor Scheu, University of Du¨sseldorf, Germany)
express the yellow ﬂuorescent protein under the IFNb promoter and therefore IFN-
I-producing cells can be detected in ﬂuorescein isothiocyanate channel30. The
spontaneous tumour models LoxP-TAg9 (liver cancer) and MT/ret (melanoma)
were used on C57BL/6 background. LoxP-TAg9 mice were provided by Professor
Willimsky (Charite, University of Berlin, Germany). MT/retmice were provided by
Dr Helfrich (University Hospital Essen, Germany). For human xenografts, NOD/
SCID mice were used (Charles River; 001303). Six- to 8-week-old, age- and sex-
matched mice were used for all the studies. All mice were maintained in single
ventilated cages, with the authorization of the Veterina¨ramt Nordrhein Westfalen
(Du¨sseldorf, Germany) in accordance with the German law for animal protection
or institutional guidelines of the Ontario Cancer Institute.
For in vivo depletion of NK cells, 50mg anti-NK1.1 (in 400ml, in house) was
injected intraperitoneally (i.p.) on days  3 and  1. For depletion of Ly-6C
and Ly-6G cells (monocytes and granulocytes), 200 mg anti-Ly6CþG antibody
(Gr-1, clone RB6-8C5, Bio X Cell BE0075) was given i.p. on days  2, 2 and 7.
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For depletion of Ly6-G cells (granulocytes), 500 mg anti-Ly6G (clone 1A8, Bio X
Cell BE0075-1) was given starting on day  2 and repeated on day 2 and day 7.
For depletion of IFNAR1, 1mg anti-IFNAR1 antibody (clone MAR1-5A3, Bio X
Cell BE0241) was given i.p. on day  1 and repeated by i.p. injections of 250mg
IFNAR1 on days 2 and 8. Same amounts of the IgG1 Isotype control (clone
MOPC21, Bio X cell) were injected to the control group. PolyI:C was provided by
Sigma (P9582).
Therapeutic application of arenavirus. The time of infection with virus was set to
day¼ 0. In subcutaneous tumour models, tumour cells where injected 13–3 days
before as stated (that is, day  10). The optimal dose to guarantee persistence of
virus in the tumour was 2 104 PFU LCMV peritumourally or 2 106 PFU
intravenously. Viral doses are indicated in the ﬁgure legends. Cell supernatant was
used for vehicle control.
Histological analysis and immunocytochemistry. Histological analysis were
performed on snap-frozen tissue as previously described67. In brief, sections
were ﬁxed with acetone for 10min and nonspeciﬁc antigens were blocked
in PBS containing 2% FCS for 15min, followed by various stainings for 45min.
Immunocytochemistry was performed on cells grown on coverslips50.
In brief, cells were ﬁxed in 4% Formalin/PBS for 10min, washed in PBS
and then permeabilized in 1% Triton X–PBS for 10min. After blocking with
10% FCS/PBS for 30–60min, various stainings for 45min were followed.
Coverslips were mounted on microscope slides using mounting medium
(S3023, Dako).
Images were acquired with a ﬂuorescence microscope (KEYENCE BZ II
analyser). Quantiﬁcations were performed using the Image J software (NIH).
Morphometric analysis of tumour vessels and hypoxia. Morphogenic analyses
were performed using consecutive cryosections stained for the endothelial cell
marker CD31. MVD was quantiﬁed by using the average of three tumour sections
per tumour (top, middle and base). For MVD and vessel–vessel distances n¼ 1,168
peritumoural vessel–vessel distances (50–100 vessels/tumour), 5 regions of interests
per sample were quantiﬁed from n¼ 3 histological samples. MVD was calculated as
number of vessels per tumour area. Vessel-to-vessel distance was calculated using
the middle section of the three generated using corresponding Cell P Software
(Olympus, Germany). For analysis of hypoxic tumour areas, Pimonidazole was
injected 30min before killing the mice. Hypoxic tumour areas were detected by the
formation of pimonidazole adducts. Tumour sections were immunostained using
the Hypoxyprobe-1 Plus kit according to the manufacturer’s protocol (Natural
Pharmacia International, Inc.) and the hypoxic area index quantiﬁed as the
percentage of positive tumour area per total tumour area in tumours of corre-
sponding volumes.
Flow cytometric analysis. Single-cell suspensions of cells were incubated with
anti-CD16/32 (anti-FcgIII/II receptor, clone 2.4G2) in a 1:100 dilution for 10min,
then stained with conjugated antibodies. All ﬂuorescently labelled monoclonal
antibodies (Supplementary Table 1) were diluted 1:100 to their original
concentration in FACS buffer. Tetramer was used from NIH tetramer core facility.
All stained cells were analysed on LSRII/FACS Fortessa (BD Biosciences) ﬂow
cytometer and data were analysed with Flowjo software.
IFN-a ELISA assay. Serum IFN-a levels were determined according to the
manufacturers’ speciﬁcations (Research Diagnostics RDI, Flanders, NJ).
Reverse transcription and qRT–PCR. Total RNA was isolated by using TRIzol
(Ambion), reverse transcribed into complementary DNA using Quantitect Reverse
Transcription Kit (Qiagen) and analysed by qRT–PCR using the SYBR Green
Master Mix (Applied Biosystems, Darmstadt, Germany) or using Taqman gene
expression assay (Life Technologies). Either commercially available Primer sets
(Supplementary Table 2–4) or self-designed primers ordered from Euroﬁns
Genomics (Ebersberg, Germany) (Supplementary Table 5) were used. For analysis,
the expression levels of all target genes were normalized to either 18S or glycer-
aldehyde 3-phosphate dehydrogenase messenger RNA expression. Relative gene
expression levels were calculated with the DCt method.
VSV assay. Cells per well (1 105) were plated in a 24-well plate on day  1. On
day 0, cells were treated with different concentrations of human IFNa4 (11100-1,
PBL Assay Science), murine IFNa4 (12115-1, PBL Assay Science) or murine IFNa2
(14-8312-62, eBiosciences) and then infected with 500 PFU/ per well VSV. After
2 h Methylcellulose overlay was added. On day 1, cell layer was stained with crystal
violet.
Small interfering RNA transient transfections. MCF7 cells were seeded at
4 104 cells per well in a 24-well plate and, 24 h later, transfected with control or
B-Myb small interfering RNA duplexes (Origene SR419327) using Hiperfect
(Qiagen 301705) as a transfection reagent. Transfected cells were infected for 24 h
with LCMV-WE, 24 h post-small interfering RNA transfection.
Statistical analysis. Mean values were compared using an unpaired Student’s
two-tailed t-test. Data are expressed as means±s.e.m. Student’s t-test was used to
detect signiﬁcant differences between groups. Chi-Quadrat test was additionally
used. Survival was compared with log-rank (Mantel–Cox) tests. The level of
statistical signiﬁcance was set at Po0.05.
Gene set enrichment analysis. RNA-sequencing gene expression data from the
TCGA for different types of cancer were downloaded using the cgdsr package of
the cBioportal gateway for Cancer Genomics (http://www.cbioportal.org) and
mRNA expression z-scores (RNA Seq V2 RSEM) used. TCGA tumours were
ranked based on CD14 expression and selected top and bottom samples used as the
input for GSEA. GSEA was performed with 1000 permutations using the Browne
IFN-response gene set.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within the article and its Supplementary Information ﬁles, or are
available from the authors upon request.
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